Results 201 to 210 of about 1,588,451 (244)

Correction: PRRX1 upregulates PD-L1 in human mesenchymal stem cells. [PDF]

open access: yesIn Vitro Cell Dev Biol Anim
Osawa T   +4 more
europepmc   +1 more source

A Celastrol–Platinum(IV) Nanoprodrug Couples Ferroptosis With Caspase‐Independent Pyroptosis to Enhance Anti‐PD‐1 Therapy in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
CPAN integrates celastrol‐driven oxidative stress with Pt(IV)‐induced DNA damage to couple ferroptosis with caspase‐independent pyroptosis. Celastrol disrupts the GSH/GPX4 axis and promotes lipid peroxidation, while Pt(IV)‐associated PARP/PARylation signaling facilitates full‐length GSDME oligomerization.
Huirong Li   +12 more
wiley   +1 more source

Vanadium Oxide Nanoregulator Modulates cGAS‐STING Pathway‐Associated Immune Dysregulation in Sepsis

open access: yesAdvanced Science, EarlyView.
This work reveals a pathogenic mitochondrial DNA‐cGAS‐STING inflammatory axis in septic patients and demonstrates that vanadium oxide nanospheres with shape‐optimized catalytic surfaces can shut down this pathway by blocking mitochondrial DNA release.
Tian Zhou   +8 more
wiley   +1 more source

PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype. [PDF]

open access: yesJ Immunother Cancer
Wang Q   +10 more
europepmc   +1 more source

Tolerogenic Immunotherapy for Type 1 Diabetes Through Sustained Autoantigen Delivery in a Transient Inflammatory Niche

open access: yesAdvanced Science, EarlyView.
Sustained co‐delivery of insulin autoantigen and low‐dose interleukin‐2 from an injectable hydrogel depot established a transient tolerogenic niche that expanded regulatory T cells and delayed median diabetes onset from 20 to >40 weeks in non‐obese diabetic mice.
Leslee T. Nguyen   +16 more
wiley   +1 more source

Can Chemoradiotherapy Expand Immune Checkpoint Blockade Responsiveness in Mismatch Repair‐Proficient Rectal Cancer?

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Immune checkpoint blockade (ICB) has transformed the treatment of mismatch repair‐deficient (dMMR) colorectal cancer but produces no meaningful benefit in advanced mismatch repair‐proficient (pMMR) disease. In the neoadjuvant setting, however, pathological responses have been reported in a subset of pMMR tumors, suggesting that clinical ...
Kimihiro Yamashita   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy